Biomarker Testing Optimizes Therapy Choice in Advanced NSCLC

Patients with advanced NSCLC who received optimal first-line treatment based on biomarker testing demonstrated better outcomes, new findings showed.

Related Keywords

United States ,Massachusetts ,American ,Adamc Powell , ,American Society Of Clinical Oncology ,Provider Syndicate ,National Comprehensive Cancer Network ,Journal Of The National Comprehensive Cancer Network ,American Society ,Clinical Oncology ,National Comprehensive Cancer ,Lung Cancer ,Ung Carcinoma ,Ancer Of The Lung ,Non Small Cell Lung Cancer ,Nsclc ,Biomarker ,Iological Marker ,Ulti Biomarker Disease Activity ,Bda ,Multibiomarker Disease Activity ,Genomics Genomic Medicine ,Small Cell Lung Cancer ,At Cell Lung Cancer ,Clc ,Biologic Therapy ,Iologics ,Otolaryngology ,Nt Specialty ,Ead And Neck Surgery Ent Speciality ,Cancer ,